Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent advances in chronic lymphocytic leukemia.

Brian L Abbott1

  • 1University of Colorado Health Science Center, Aurora, Colorado, USA. Brian.Abbott@uchsc.edu

Cancer Investigation
|July 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.

Clinical therapeutics·2012
Same author

Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway.

Journal of cell science·2007
Same author

Treatment of HIV-associated Burkitt Lymphoma in the presence of severe hepatic dysfunction.

Clinical advances in hematology & oncology : H&O·2006
Same author

Diagnosis and management of lymphoma.

Clinical lymphoma & myeloma·2006
Same author

ABCG2 (BCRP): a cytoprotectant in normal and malignant stem cells.

Clinical advances in hematology & oncology : H&O·2006
Same author

Chronic lymphocytic leukemia: recent advances in diagnosis and treatment.

The oncologist·2006

Chronic lymphocytic leukemia (CLL) is a heterogeneous malignancy. Many low-risk patients may not need treatment, while newer therapies offer improved outcomes for others.

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) is a B-lineage lymphoid malignancy.
  • Recent findings reveal significant heterogeneity within CLL, challenging previous assumptions.
  • Many CLL cases are low-grade and may not require immediate intervention.

Purpose of the Study:

  • To discuss the heterogeneity of chronic lymphocytic leukemia.
  • To outline risk-based treatment strategies for CLL.
  • To review recent advancements in CLL management.

Main Methods:

  • Review of recent molecular risk features in CLL.
  • Analysis of newer treatment regimens including purine analogs and monoclonal antibodies.
  • Evaluation of reduced intensity conditioning for allogeneic transplantation.

Related Experiment Videos

Main Results:

  • CLL exhibits greater heterogeneity than previously recognized.
  • Molecular risk features aid in predicting disease course.
  • Novel therapies improve molecular remission rates and survival.
  • Allogeneic transplantation is more accessible with reduced intensity regimens.

Conclusions:

  • Treatment decisions for CLL should be guided by risk stratification.
  • Many asymptomatic, low-risk CLL patients may not require treatment.
  • Newer treatments offer improved outcomes but carry infectious risks.
  • A risk-based algorithm can guide CLL management.